H.C. Wainwright analyst Robert Burns initiated coverage of Immix Biopharma with a Buy rating and $7 price target. Powered by its N-GENUS platform, Immix is advancing potentially differentiated cell therapies, the analyst tells investors in a research note. The firm says NXC-201 has demonstrated encouraging initial results in AL amyloidosis.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMX:
- Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
- Immix Biopharma Shareholders Back Growth and Governance Changes
- Immix Biopharma announces NXC-201 relapsed/refractory AL Amyloidosis data
- Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
- Immix Biopharma management to meet with B. Riley